MX9204256A - Formulaciones para dosificacion oral mejoradas de nucleosidos de dideoxi purina. - Google Patents

Formulaciones para dosificacion oral mejoradas de nucleosidos de dideoxi purina.

Info

Publication number
MX9204256A
MX9204256A MX9204256A MX9204256A MX9204256A MX 9204256 A MX9204256 A MX 9204256A MX 9204256 A MX9204256 A MX 9204256A MX 9204256 A MX9204256 A MX 9204256A MX 9204256 A MX9204256 A MX 9204256A
Authority
MX
Mexico
Prior art keywords
oral dosage
improved oral
dosage formulations
dideoxi
nucleosides
Prior art date
Application number
MX9204256A
Other languages
English (en)
Spanish (es)
Inventor
Ismat Ullah
Shreeram Narahari Agharkar
Gary James Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27112590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9204256(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX9204256A publication Critical patent/MX9204256A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
MX9204256A 1991-07-22 1992-07-21 Formulaciones para dosificacion oral mejoradas de nucleosidos de dideoxi purina. MX9204256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73354791A 1991-07-22 1991-07-22
US88220492A 1992-05-13 1992-05-13

Publications (1)

Publication Number Publication Date
MX9204256A true MX9204256A (es) 1993-01-01

Family

ID=27112590

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9204256A MX9204256A (es) 1991-07-22 1992-07-21 Formulaciones para dosificacion oral mejoradas de nucleosidos de dideoxi purina.

Country Status (23)

Country Link
US (1) US5880106A (enExample)
EP (1) EP0524579B1 (enExample)
JP (1) JP3038456B2 (enExample)
KR (1) KR960011772B1 (enExample)
CN (1) CN1042299C (enExample)
AT (1) ATE163855T1 (enExample)
AU (1) AU657337B2 (enExample)
CA (1) CA2074215C (enExample)
DE (1) DE69224684T2 (enExample)
DK (1) DK0524579T3 (enExample)
ES (1) ES2113389T3 (enExample)
FI (1) FI105153B (enExample)
GR (1) GR3026332T3 (enExample)
HU (3) HU9202318D0 (enExample)
IE (1) IE922365A1 (enExample)
IL (1) IL102519A (enExample)
MX (1) MX9204256A (enExample)
NO (1) NO300198B1 (enExample)
NZ (1) NZ243567A (enExample)
PL (1) PL295329A1 (enExample)
RU (1) RU2089193C1 (enExample)
TW (1) TW211521B (enExample)
ZA (1) ZA925484B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
CN1325305A (zh) * 1998-06-18 2001-12-05 乔治华盛顿大学 以低的副作用施用喜树碱化合物治疗癌症的方法
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
US20040028772A1 (en) * 2000-08-14 2004-02-12 Carsten Andersen Method for preparation of chewing gum with customer acceptable taste
US6887926B1 (en) 2001-11-16 2005-05-03 Oatey Co. Bonding compositions for chlorinated polymers and methods of using the same
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
RU2276992C2 (ru) * 2004-07-12 2006-05-27 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Фармацевтический состав, обладающий ноотропной активностью
US20080299227A1 (en) * 2007-05-30 2008-12-04 Sunhealth Therapies, Inc. Method for removal of HIV from the gastrointestinal tract and bile of HIV-infected subjects and for the prevention of drug failure and prevention of development of AIDS in HIV-infected subjects
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
EA019341B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
LT2609923T (lt) 2010-03-31 2017-09-11 Gilead Pharmasset Llc (s)-izopropilo 2-(((s)-(perfluorfenoksi)(fenoksi)fosforil)amino)-propanoato kristalinimo būdas
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
CN102949406B (zh) * 2011-08-31 2014-03-12 天津药物研究院 一种复方艾夫他滨药物组合物及其制备方法和用途
AR089857A1 (es) * 2012-02-02 2014-09-24 Glaxosmithkline Llc Comprimido antiacido para refrescar el aliento
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
CN104069126A (zh) * 2014-07-02 2014-10-01 浙江康乐药业股份有限公司 一种治疗胃酸过多的药物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260596A (en) * 1979-08-13 1981-04-07 Bristol-Myers Company Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4921707A (en) * 1986-06-24 1990-05-01 Istvan Racz Proceeding for the production of pharmaceutical preparations of high gastric acid binding capacity, of retarded effect and of increased bioavailability
WO1988002629A1 (en) * 1986-10-16 1988-04-21 American Health Products Corporation 2',3'-didesoxyadenosine composition
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds

Also Published As

Publication number Publication date
ATE163855T1 (de) 1998-03-15
HU9202375D0 (en) 1992-10-28
NO300198B1 (no) 1997-04-28
IE922365A1 (en) 1992-11-18
FI105153B (fi) 2000-06-30
PL295329A1 (en) 1993-04-05
IL102519A (en) 1996-01-31
RU2089193C1 (ru) 1997-09-10
EP0524579A1 (en) 1993-01-27
KR930001912A (ko) 1993-02-22
CA2074215C (en) 2001-12-18
NO922807L (no) 1993-01-25
HUT61472A (en) 1993-01-28
DE69224684D1 (de) 1998-04-16
GR3026332T3 (en) 1998-06-30
AU2039692A (en) 1993-01-28
NO922807D0 (no) 1992-07-16
HU9202318D0 (en) 1992-10-28
TW211521B (enExample) 1993-08-21
NZ243567A (en) 1995-04-27
ES2113389T3 (es) 1998-05-01
EP0524579B1 (en) 1998-03-11
JP3038456B2 (ja) 2000-05-08
DE69224684T2 (de) 1998-11-12
CN1042299C (zh) 1999-03-03
CN1068739A (zh) 1993-02-10
HU211285A9 (en) 1995-11-28
HU220612B1 (hu) 2002-03-28
IL102519A0 (en) 1993-01-14
ZA925484B (en) 1993-09-13
FI923308A0 (fi) 1992-07-20
DK0524579T3 (da) 1998-04-06
FI923308L (fi) 1993-01-23
AU657337B2 (en) 1995-03-09
US5880106A (en) 1999-03-09
JPH05194234A (ja) 1993-08-03
CA2074215A1 (en) 1993-01-23
KR960011772B1 (ko) 1996-08-30

Similar Documents

Publication Publication Date Title
MX9204256A (es) Formulaciones para dosificacion oral mejoradas de nucleosidos de dideoxi purina.
IT1211484B (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
ATE125155T1 (de) Niedrigdosierte getrocknete pharmazeutische präparate.
PT90466A (pt) Processo de preparacao de composicoes farmaceuticas compreendendo um excipiente extragranular, higroscopio insoluvel em agua e um ingrediente activo, em particular a cimetidina
DE69211688D1 (de) Kaubare antacida
ITRM910038A1 (it) Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.
ITMI920903A1 (it) Composizioni farmaceutiche somministrabili per via orale a rilascio mirato contenenti acido ursodesossicolico ed acido chenodesossicolico.
TH6020B (th) สูตรผสมเมนาไดโอนไบซัลโฟท์ที่ได้ทำให้เสถียร และการเตรียมสูตรผสมเหล่านี้
TH13488A (th) สูตรผสมซึ่งให้ทางปากที่ดีขึ้นของไดดีออกซีพิวรีนนิวคลีโอไซด์